FGF23 and chronic kidney disease: • Use of SNPs associated with serum uric acid to assess risk of CKD or SNPs related to FGF23 for cardiovascular outcomes.• Independence of these SNPs from other CKD or ESRD confounders.• Testing for pleiotropy (MR-Egger, weighted median).